Skip to main content

Table 2 Women per week by initial treatment within 3 months of diagnosis, diagnosis period, and stage

From: Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

  Total Untreated BCS Mx with IBR Mx without IBR Chemotherapy Hormonal treatment Other
DCIS         
 2018/2019, wk 2–17 42.8 3.9 (9.1) 27.9 (65.2) 5.0 (11.8) 5.4 (12.6) 0.2 (0.4) 0.4 (0.9) 0.0 (0.2)
 2020, wk 2–8 49.7 8.1 (16.4) ↑ 29.7 (59.8) 5.1 (10.3) 6.4 (12.9) 0.1 (0.3) 0.1 (0.3) 0.0 (0.0)
 2020, wk 9–11 41.3 7.3 (17.7) ↑ 22.7 (54.8) 3.7 (8.9) 7.0 (16.9) 0.0 (0.0) 0.7 (1.6) 0.0 (0.0)
 2020, wk 12–13 32.0 3.5 (10.9) 19.5 (60.9)a 2.0 (6.3) 5.5 (17.2) 0.0 (0.0) 1.5 (4.7)b 0.0 (0.0)
 2020, wk 14–17 9.8 1.0 (10.3) 4.5 (46.2) 2.0 (20.5) 1.8 (17.9) 0.3 (2.6) 0.3 (2.6) 0.0 (0.0)
Stage I         
 2018/2019, wk 2–17 147.0 2.7 (1.8) 103.0 (70.1) 10.1 (6.9) 16.8 (11.4) 7.1 (4.8) 7.3 (4.9) 0.2 (0.1)
 2020, wk 2–8 153.1 2.6 (1.7) 104.6 (68.3) 8.9 (5.8)c 18.0 (11.8) 9.1 (6.0) 9.9 (6.4) 0.1 (0.1)
 2020, wk 9–11 138.7 1.7 (1.2) 95.0 (68.5) 10.0 (7.2) 17.7 (12.7) 2.3 (1.7) ↓ 12.0 (8.7)d 0.0 (0.0)
 2020, wk 12–13 83.5 1.0 (1.2) 55.5 (66.5) 3.5 (4.2) 9.5 (11.4) 3.0 (3.6) 11.0 (13.2)e 0.0 (0.0)
 2020, wk 14–17 52.5 0.8 (1.4) 29.0 (55.2) ↓ 4.8 (9.0) 7.5 (14.3) 5.0 (9.5) ↑ 5.5 (10.5) ↑ 0.0 (0.0)
Stage II         
 2018/2019, wk 2–17 119.1 2.6 (2.2) 36.3 (30.5) 5.3 (4.5) 20.9 (17.6) 37.5 (31.5) 16.0 (13.4) 0.4 (0.4)
 2020, wk 2–8 127.1 2.9 (2.2) 35.9 (28.2) 5.9 (4.6) 21.7 (17.1) 38.7 (30.4) 21.9 (17.2)f 0.3 (0.2)
 2020, wk 9–11 105.3 3.3 (3.2) 32.0 (30.4) 3.3 (3.2) 20.0 (19.0) 22.7 (21.5) ↓ 24.0 (22.8)d 0.0 (0.0)
 2020, wk 12–13 71.0 1.0 (1.4) 22.5 (31.7) 1.5 (2.1) 10.5 (14.8) 20.0 (28.2) 15.5 (21.8)g 0.0 (0.0)
 2020, wk 14–17 66.0 1.0 (1.5) 17.3 (26.1) 2.0 (3.0) 12.3 (18.6) 22.5 (34.1) 11.0 (16.7) 0.0 (0.0)
Stage III         
 2018/2019, wk 2–17 32.7 0.8 (2.6) 2.0 (6.2) 0.6 (1.8) 5.9 (18.1) 17.5 (53.6) 5.3 (16.2) 0.5 (1.4)
 2020, wk 2–8 29.9 1.1 (3.8) 2.4 (8.1) 0.4 (1.4) 6.0 (20.1) 14.4 (48.3) 5.4 (18.2) 0.0 (0.0)
 2020, wk 9–11 27.3 0.3 (1.2) 1.3 (4.9) 0.3 (1.2) 5.3 (19.5) 14.0 (51.2)h 6.0 (22.0) 0.0 (0.0)
 2020, wk 12–13 17.5 0.0 (0.0) 0.5 (2.9) 1.5 (8.6) ↑ 2.5 (14.3) 6.0 (34.3) 7.0 (40.0)i 0.0 (0.0)
 2020, wk 14–17 15.5 0.3 (1.6) 0.8 (4.8) 1.0 (6.5) ↑ 2.3 (14.5) 9.3 (59.7) 2.0 (12.9) 0.0 (0.0)
Stage IV         
 2018/2019, wk 2–17 17.2 1.6 (9.3) 0.3 (2.0) 0.0 (0.2) 0.6 (3.5) 5.7 (33.3) 7.4 (43.3) 1.5 (8.5)
 2020, wk 2–8 19.1 3.1 (16.4) ↑ 0.4 (2.2) 0.0 (0.0) 0.9 (4.5) 6.3 (32.8) 7.4 (38.8) 1.0 (5.2)
 2020, wk 9–11 16.3 2.0 (12.2) 0.7 (4.1) 0.0 (0.0) 0.7 (4.1) 5.3 (32.7)j 7.7 (46.9) 0.0 (0.0)
 2020, wk 12–13 12.0 1.0 (8.3) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 3.5 (29.2)k 7.5 (62.5) ↑ 0.0 (0.0)
 2020, wk 14–17 13.5 1.5 (11.1) 0.0 (0.0) 0.0 (0.0) 0.3 (1.9) 5.8 (42.6)l 5.3 (38.9)m 0.8 (5.6)
  1. Data are shown as average n (%). We compared data for weeks 2–17, 2020 (the COVID-19 period) with those for weeks 2–17, 2018/2019 using the Mantel–Haenszel test, adjusted by age (< 40, 40–50, 50–65, 65–74, > 74 years)
  2. The arrows show statistically significant data corrected for age: ↑ = more patients received this therapy; ↓ = fewer patients received this therapy
  3. BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; IBR, immediate breast reconstruction; Mx, mastectomy; wk, week
  4. Analyses stratified per age group was performed and significant differences are explained:
  5. aLower proportion of patients 65–74 years old with DCIS received BCS
  6. bHigher proportion of patients 65–74 years old with DCIS received hormonal treatment
  7. cHigher proportion of patients < 40 years old with stage I received mastectomy with IBR
  8. dHigher proportion of patients 50–74 years old with stage I or stage II received hormonal treatment
  9. eHigher proportion of patients < 75 years old with stage I received hormonal treatment
  10. fHigher proportion of patients 40–74 years old with stage II received hormonal treatment
  11. gHigher proportion of patients < 50 years old or > 74 years old with stage II received hormonal treatment
  12. hHigher proportion of patients < 40 years old with stage III received chemotherapy
  13. iHigher proportion of patients < 50 years old or 65–74 years old with stage III received hormonal treatment
  14. jHigher proportion of patients < 40 years old with stage IV received chemotherapy
  15. kHigher proportion of patients 40–49 years old with stage IV received chemotherapy
  16. lHigher proportion of patients aged < 40 years old or 50–64 years old with stage IV received chemotherapy
  17. mHigher proportion of patients 40–49 years old or 65–74 years old with stage IV received hormonal treatment